SG11201906041QA - Pharmaceutical compositions for combination therapy - Google Patents
Pharmaceutical compositions for combination therapyInfo
- Publication number
- SG11201906041QA SG11201906041QA SG11201906041QA SG11201906041QA SG11201906041QA SG 11201906041Q A SG11201906041Q A SG 11201906041QA SG 11201906041Q A SG11201906041Q A SG 11201906041QA SG 11201906041Q A SG11201906041Q A SG 11201906041QA SG 11201906041Q A SG11201906041Q A SG 11201906041QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- loos
- english
- january
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 3
- 239000013066 combination product Substances 0.000 abstract 1
- 229940127555 combination product Drugs 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305094 | 2017-01-27 | ||
| EP17305268 | 2017-03-13 | ||
| EP17190723 | 2017-09-12 | ||
| PCT/EP2018/052159 WO2018138352A1 (en) | 2017-01-27 | 2018-01-29 | Pharmaceutical compositions for combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906041QA true SG11201906041QA (en) | 2019-08-27 |
Family
ID=61157183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906041QA SG11201906041QA (en) | 2017-01-27 | 2018-01-29 | Pharmaceutical compositions for combination therapy |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11033534B2 (de) |
| EP (1) | EP3573614A1 (de) |
| JP (1) | JP7224294B2 (de) |
| KR (1) | KR102537043B1 (de) |
| CN (1) | CN110198708B (de) |
| AU (1) | AU2018212614B2 (de) |
| BR (1) | BR112019015406A2 (de) |
| CA (1) | CA3046158A1 (de) |
| CO (1) | CO2019008103A2 (de) |
| IL (1) | IL267703B (de) |
| MX (1) | MX2019008917A (de) |
| PH (1) | PH12019501301A1 (de) |
| SG (1) | SG11201906041QA (de) |
| WO (1) | WO2018138352A1 (de) |
| ZA (1) | ZA201905510B (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170290814A1 (en) * | 2016-04-11 | 2017-10-12 | Genfit | Methods of treatment of cholestasis and fibrosis |
| US11590108B2 (en) * | 2017-02-24 | 2023-02-28 | Genfit | Pharmaceutical compositions for combination therapy |
| CN110025621A (zh) * | 2019-03-13 | 2019-07-19 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 替唑尼特和硝唑尼特在制备抗炎药物中的应用 |
| MA55588A (fr) * | 2019-04-09 | 2022-02-16 | Genfit | Combinaison de nitazoxanide et d'elafibranor pour le traitement de maladies immunitaires ou d'une inflammation |
| WO2020208208A1 (en) * | 2019-04-12 | 2020-10-15 | Genfit | Nitazoxanide and thiazolides for use in the treatment of diseases associated with oxidative stress |
| KR102199640B1 (ko) * | 2020-01-06 | 2021-01-07 | 브렉소젠 주식회사 | 라니피브라노르를 포함하는 줄기세포 유래 엑소좀 생성 촉진 및 줄기세포기능 강화용 조성물 |
| AU2020376223A1 (en) * | 2019-10-28 | 2022-06-02 | Genfit | Combination therapy having antioxydant properties |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| WO2022051323A1 (en) * | 2020-09-03 | 2022-03-10 | Coherus Biosciences, Inc. | Fixed dose combinations of chs-131 and a ppar agonist |
| CN114044761B (zh) * | 2021-02-24 | 2022-05-17 | 成都贝诺科成生物科技有限公司 | 一种新的硝基噻唑衍生物及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1437800A (en) | 1973-08-08 | 1976-06-03 | Phavic Sprl | Derivatives of 2-benzamido-5-nitro-thiazoles |
| AU2007204963B2 (en) * | 2006-01-09 | 2012-09-27 | Romark Laboratories, L.C. | Viral hepatitis treatment |
| WO2012100436A1 (en) * | 2011-01-30 | 2012-08-02 | Curegenix Inc. | Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof |
| KR20200006177A (ko) | 2011-03-02 | 2020-01-17 | 제롬 쉔타그 | 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단 |
-
2018
- 2018-01-29 SG SG11201906041QA patent/SG11201906041QA/en unknown
- 2018-01-29 KR KR1020197024250A patent/KR102537043B1/ko active IP Right Grant
- 2018-01-29 BR BR112019015406A patent/BR112019015406A2/pt active Search and Examination
- 2018-01-29 MX MX2019008917A patent/MX2019008917A/es unknown
- 2018-01-29 US US16/479,382 patent/US11033534B2/en active Active
- 2018-01-29 CN CN201880008087.3A patent/CN110198708B/zh active Active
- 2018-01-29 JP JP2019541179A patent/JP7224294B2/ja active Active
- 2018-01-29 CA CA3046158A patent/CA3046158A1/en active Pending
- 2018-01-29 EP EP18702961.6A patent/EP3573614A1/de active Pending
- 2018-01-29 AU AU2018212614A patent/AU2018212614B2/en active Active
- 2018-01-29 WO PCT/EP2018/052159 patent/WO2018138352A1/en active Application Filing
-
2019
- 2019-06-10 PH PH12019501301A patent/PH12019501301A1/en unknown
- 2019-06-27 IL IL267703A patent/IL267703B/en unknown
- 2019-07-26 CO CONC2019/0008103A patent/CO2019008103A2/es unknown
- 2019-08-21 ZA ZA2019/05510A patent/ZA201905510B/en unknown
-
2021
- 2021-05-10 US US17/316,115 patent/US12053456B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CO2019008103A2 (es) | 2019-08-20 |
| KR102537043B1 (ko) | 2023-05-25 |
| CN110198708A (zh) | 2019-09-03 |
| US12053456B2 (en) | 2024-08-06 |
| US20210275504A1 (en) | 2021-09-09 |
| AU2018212614B2 (en) | 2024-02-01 |
| MX2019008917A (es) | 2019-12-09 |
| EP3573614A1 (de) | 2019-12-04 |
| CA3046158A1 (en) | 2018-08-02 |
| IL267703A (en) | 2019-08-29 |
| ZA201905510B (en) | 2023-03-29 |
| WO2018138352A1 (en) | 2018-08-02 |
| AU2018212614A1 (en) | 2019-06-27 |
| JP7224294B2 (ja) | 2023-02-17 |
| JP2020506920A (ja) | 2020-03-05 |
| PH12019501301A1 (en) | 2019-12-11 |
| US11033534B2 (en) | 2021-06-15 |
| CN110198708B (zh) | 2022-09-20 |
| US20190388398A1 (en) | 2019-12-26 |
| KR20190108141A (ko) | 2019-09-23 |
| BR112019015406A2 (pt) | 2020-05-19 |
| IL267703B (en) | 2022-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201906041QA (en) | Pharmaceutical compositions for combination therapy | |
| SG11201909168VA (en) | Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor | |
| SG11201907673YA (en) | Pharmaceutical compositions for combination therapy | |
| SG11201901390TA (en) | Tetracycline compounds and methods of treatment | |
| SG11201906987RA (en) | Combination of a ppar agonist with a fxr agonist | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201908740VA (en) | Sustained release delivery systems comprising traceless linkers | |
| SG11201910191RA (en) | A peptide capable of forming a gel for use in tissue engineering and bioprinting | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201806845VA (en) | Moisturizing compositions and uses thereof | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201901494UA (en) | Acid-alpha glucosidase variants and uses thereof | |
| SG11201903938XA (en) | Acylated glp-1/glp-2 dual agonists | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201806868TA (en) | Compositions and methods for protecting against airborne pathogens and irritants | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201807549TA (en) | Combination of a cxcr4 antagonist and an immune checkpoint inhibitor | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201906313SA (en) | A polypeptide linker for preparing multispecific antibodies | |
| SG11202000494UA (en) | Drug delivery composition |